Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

Take our second thesis — please! (Protective orders)

By Bexis on December 18, 2006
Email this postTweet this postLike this postShare this post on LinkedIn

Cover stories in both yesterday’s and today’s New York Times criticize Eli Lilly’s marketing of Zyprexa based on internal documents provided by a plaintiff’s lawyer. The lawyer appears to have a clear conscience — his name and photograph appear in Sunday’s article, so no court would have any trouble tracking him down. Lilly, on the other hand, appears to be outraged. The documents were originally provided to plaintiffs’ lawyers under seal, and Lilly insists that the release of the documents is “illegal.” As to this particular release of documents, we (or at least the one of us typing these words) have no idea whether the documents were released lawfully or not. But it seems as though, in general, we’ve seen this film before.

Doesn’t this happen in virtually all of the mass torts? Courts enter protective orders; defendants produce documents subject to the protective orders; documents are leaked to the press; night follows day.

What surprises us is how infrequently courts seem to care about this. Although documents are often leaked in violation of mass tort protective orders, courts rarely conduct full-scale investigations to find and punish the person who violated the court’s order. Why not?

We’d like to see an academic (who might have the time to pursue this) research the mass tort cases (since about 1985 or so, when modern mass torts sprung into being) to determine the percentage of cases in which protective orders have been violated and the number of times courts have tracked down and punished the violator. If, as we suspect, protective orders are routinely ignored, but violators are rarely punished, that fact should influence how courts conduct future cases. If courts can’t honestly tell defendants that protective orders will be enforced, what should follow from that? Should particularly sensitive documents not be produced at all? Should document depositories be protected more carefully? Are there other implications for future cases?

We understand that some lawyers who leak confidential documents may believe that they’re serving the public good. But other leakers are unfairly trying their cases in the court of public opinion, with the aim of either pressuring a defendant to settle or poisoning the minds of potential jurors. If a lawyer wants to give documents to a newspaper to serve the public good, then the lawyer should do so lawfully. If documents should be unsealed, file a motion to unseal them. Don’t simply leak them illegally to the press.

Again, we don’t know anything at all about the propriety of the leak in the Zyprexa case. But we’ve seen and read about leaks in an awful lot of mass tort cases in the past. It’s time for the judicial system to decide how it will respond in cases where leaks in fact violate court orders.

Photo of Bexis Bexis

JAMES M. BECK is Reed Smith’s only Senior Life Sciences Policy Analyst, resident in the firm’s Philadelphia office. He is the author of, among other things, Drug and Medical Device Product Liability Handbook (2004) (with Anthony Vale). He wrote the seminal law review…

JAMES M. BECK is Reed Smith’s only Senior Life Sciences Policy Analyst, resident in the firm’s Philadelphia office. He is the author of, among other things, Drug and Medical Device Product Liability Handbook (2004) (with Anthony Vale). He wrote the seminal law review article on off-label use cited by the Supreme Court in Buckman v. Plaintiffs Legal Committee. He has written more amicus briefs for the Product Liability Advisory Council than anyone else in the history of the organization, and in 2011 won PLAC’s highest honor, the John P. Raleigh award. He has been a member of the American Law Institute (ALI) since 2005. He is the long-time editor of the newsletter of the ABA’s Mass Torts Committee.  He is vice chair of the Class Actions and Multi-Plaintiff Litigation SLG of DRI’s Drug and Device Committee.  He can be reached at jmbeck@reedsmith.com.  His LinkedIn page is here.

Read more about BexisEmailJames's Linkedin Profile
Show more Show less
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Drug & Device Law
  • Organization:
    Drug & Device Law Blogging Team
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo